Svoronos Dawn
Known title: DirectorCIK: 0001574579
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
Transaction History
| XENE | ▲ Buy | Option Exercise | 5,144 | $42K | 9/1/2026 | View on chart |
| XENE | ▲ Buy | Option Exercise | 2,645 | — | 6/1/2026 | View on chart |
| XENE | ▼ Sell | Tax Withholding | 1,416 | $76K | 6/1/2026 | View on chart |
| XENE | ▼ Sell | Open Market | 25,000 | $968K | 8/24/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 738 | $20K | 6/9/2022 | View on chart |
| PTCT | ▼ Sell | Open Market | 510 | $20K | 1/7/2022 | View on chart |
| PTCT | ▲ Buy | Grant | 3,200 | $0 | 1/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Xenon (XENE) sees insider buying and new analyst price target
Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).
Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).